Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 8/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664476 | 0.75 | BRD4 (0.44) | BRD4RORCPDE10ATRPM5 | |
| SCHEMBL16692277 | 0.69 | GCK (0.33) | TRPM5 | |
| SCHEMBL23416651 | 0.68 | CCR1 (0.31) | — | |
| SCHEMBL7914448 | 0.67 | CCR1 (0.32) | OPRK1 | |
| SCHEMBL16663588 | 0.67 | RORC (0.34) | RORC | |
| SCHEMBL10688235 | 0.65 | BRD4 (0.33) | BRD4PDE10A | |
| SCHEMBL16664441 | 0.65 | ALDH1A1 (0.35) | BRD4RORC | |
| SCHEMBL23416654 | 0.65 | NISCH (0.31) | — | |
| SCHEMBL23416752 | 0.65 | — | — | |
| SCHEMBL16664453 | 0.64 | HRH4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2017-11-02 | — | — | US | disclosed |
| US-9657033-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | BRD4 120/4885RORC 1/4885PDE10A 1522/4885 |
| US-20150111877-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | BRD4 120/4885RORC 1/4885PDE10A 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.